Interactions of HIV-1 and HIV-2 in West Africa

2002 ◽  
Author(s):  
Phyllis J. Kanki
Keyword(s):  
1995 ◽  
Vol 2 (3) ◽  
pp. 174-177 ◽  
Author(s):  
Thomas R. Eng ◽  
Thomas R. O'Brien ◽  
Kenneth W. Bernard ◽  
Charles A. Schable ◽  
Theresa van der Vlugt ◽  
...  
Keyword(s):  

Author(s):  
Kate El Bouzidi ◽  
Steven A Kemp ◽  
Rawlings P Datir ◽  
Fati Murtala-Ibrahim ◽  
Ahmad Aliyu ◽  
...  

Abstract Objectives HIV-1 integrase inhibitors are recommended as first-line therapy by WHO, though efficacy and resistance data for non-B subtypes are limited. Two recent trials have identified the integrase L74I mutation to be associated with integrase inhibitor treatment failure in HIV-1 non-B subtypes. We sought to define the prevalence of integrase resistance mutations, including L74I, in West Africa. Methods We studied a Nigerian cohort of recipients prior to and during receipt of second-line PI-based therapy, who were integrase inhibitor-naive. Illumina next-generation sequencing with target enrichment was used on stored plasma samples. Drug resistance was interpreted using the Stanford Resistance Database and the IAS-USA 2019 mutation lists. Results Of 115 individuals, 59.1% harboured CRF02_AG HIV-1 and 40.9% harboured subtype G HIV-1. Four participants had major IAS-USA integrase resistance-associated mutations detected at low levels (2%–5% frequency). Two had Q148K minority variants and two had R263K (one of whom also had L74I). L74I was detected in plasma samples at over 2% frequency in 40% (46/115). Twelve (26.1%) had low-level minority variants of between 2% and 20% of the viral population sampled. The remaining 34 (73.9%) had L74I present at >20% frequency. L74I was more common among those with subtype G infection (55.3%, 26/47) than those with CRF02_AG infection (29.4%, 20/68) (P = 0.005). Conclusions HIV-1 subtypes circulating in West Africa appear to have very low prevalence of major integrase mutations, but significant prevalence of L74I. A combination of in vitro and clinical studies is warranted to understand the potential implications.


2002 ◽  
Vol 29 (5) ◽  
pp. 511-516
Author(s):  
Larry W. Chang ◽  
Muberak Osei-Kwasi ◽  
Daniel Boakye ◽  
Simeon Aidoo ◽  
Angela Hagy ◽  
...  

2019 ◽  
Vol 5 (Supplement_1) ◽  
Author(s):  
M T Boswell ◽  
A Palm ◽  
S Karlson ◽  
F Månsson ◽  
H Norrgren ◽  
...  

Abstract The human immunodeficiency virus type 2 (HIV-2) is an important cause of acquired immune deficiency syndrome (AIDS) in West Africa. The virus started circulating in humans around 1938 and has spread predominantly within West Africa with an estimated 1–2 million people being infected today. Compared with the pandemic HIV-1, HIV-2 infected people have longer AIDS-free survival times, higher CD4+ counts and lower risk of vertical and horizontal transmission. Approximately 35 per cent of HIV-2 infected individuals are classified as so-called long-term non-progressors with undetectable viral loads and limited disease progression after 10 years of follow-up. It has been shown that HIV-2 is more sensitive to the host restriction factor TRIM5α when compared with HIV-1, and this has been linked to conformational changes in the retroviral capsid. TRIM5α binds at the interface between three capsid hexamers, initiates early uncoating and proteasomal degradation. TRIM5 genotype has shown only modest effects on HIV-1 disease outcomes. HIV-2 capsid sequences bearing a specific poly-proline motif have been associated with lower viral loads and presentation of protective HLA I-restricted epitopes. The major aims of this study were to (1) determine HIV-2 capsid intra-host evolutionary rates and (2) identify residues that are affected by positive selection and that can be linked to HIV-2 viral load and disease progression in conjunction with TRIM5 genotype. The Guinea-Bissau Police cohort is unique, with decades of relatively frequent follow-up. One hundred and sixty-five patients were included for genotyping of TRIM5, 62 females and 103 males. Median age at enrolment was 52.6 years (range 30–87) and 7.9 per cent of patients had a CD4 percentage < 15 per cent at enrolment. Six of these individuals were included for amplification of HIV-2 capsid from longitudinally collected samples. Viral RNA was extracted from stored blood plasma samples and capsid of the circulating viral quasispecies was amplified, cloned, and sequenced, as previously described. Bayesian analysis will be used to determine intra-host evolutionary rates, dN/dS ratios and how these parameters associate with disease progression and TRIM5 genotype.


AIDS ◽  
1988 ◽  
Vol 2 (6) ◽  
pp. 433-436 ◽  
Author(s):  
Michel Gody ◽  
Soungalo A. Ouattara ◽  
Guy de Thé

2006 ◽  
Vol 38 (11-12) ◽  
pp. 1050-1056 ◽  
Author(s):  
Ramu Sarge-Njie ◽  
Maarten Schim Van Der Loeff ◽  
Saihou Ceesay ◽  
David Cubitt ◽  
Saihou Sabally ◽  
...  

2011 ◽  
Vol 2011 ◽  
pp. 1-11 ◽  
Author(s):  
Kevin Peterson ◽  
Sabelle Jallow ◽  
Sarah L. Rowland-Jones ◽  
Thushan I. de Silva

HIV-2 contributes approximately a third to the prevalence of HIV in West Africa and is present in significant amounts in several low-income countries outside of West Africa with historical ties to Portugal. It complicates HIV diagnosis, requiring more expensive and technically demanding testing algorithms. Natural polymorphisms and patterns in the development of resistance to antiretrovirals are reviewed, along with their implications for antiretroviral therapy. Nonnucleoside reverse transcriptase inhibitors, crucial in standard first-line regimens for HIV-1 in many low-income settings, have no effect on HIV-2. Nucleoside analogues alone are not sufficiently potent enough to achieve durable virologic control. Some protease inhibitors, in particular those without ritonavir boosting, are not sufficiently effective against HIV-2. Following review of the available evidence and taking the structure and challenges of antiretroviral care in West Africa into consideration, the authors make recommendations and highlight the needs of special populations.


2002 ◽  
Vol 29 (5) ◽  
pp. 511-516 ◽  
Author(s):  
Larry W. Chang ◽  
Muberak Osei-Kwasi ◽  
Daniel Boakye ◽  
Simeon Aidoo ◽  
Angela Hagy ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document